Skip to Main Content

Paper Details

Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.
J Card Fail
0
2023
CAD, Empagliflozin, HF, HFrEF, Heart Failure, PAD, Participants, Vascular Disease, Vascular disease, cardiovascular, cerebrovascular disease, coronary artery disease, diabetes, empagliflozin, heart failure, hypertension, ischemic heart disease, monovascular disease, participants, patients, peripheral artery disease, person, polyvascular, polyvascular disease, vascular disease
Author NameAffiliation
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon
Ileana L Pi??aThomas Jefferson University
Milton PackerBaylor University Medical Center, USA Imperial College
  • 1 - 3

Datasets

Release 1.2